Nutrition
Volume 26, Issue 10 , Pages 975-980 , October 2010

Apolipoprotein A-I positively associated with diabetes in women independently of apolipoprotein E genotype and apolipoprotein B levels

  • Altan Onat, M.D.

      Affiliations

    • Turkish Society of Cardiology, Istanbul University, Istanbul, Turkey
    • Cerrahpaşa Medical Faculty, Istanbul University, Istanbul, Turkey
    • Corresponding Author InformationCorresponding author. Tel.: +90-212-351-6217; fax: +90-212-351-4235.
    • ,
  • Evrim Kömürcü-Bayrak, M.S.

      Affiliations

    • Department of Genetics, Institute for Experimental Medical Research, Istanbul University, Istanbul, Turkey
    • ,
  • Günay Can, M.D.

      Affiliations

    • Cerrahpaşa Medical Faculty, Istanbul University, Istanbul, Turkey
    • ,
  • Zekeriya Küçükdurmaz, M.D.

      Affiliations

    • Department of Cardiology, Medical Faculty, Gaziantep University, Gaziantep, Turkey
    • ,
  • Gülay Hergenç, Ph.D.

      Affiliations

    • Biology Department, Yildiz Technical University, Istanbul, Turkey
    • ,
  • Nihan Erginel-Unaltuna, Ph.D.

      Affiliations

    • Department of Genetics, Institute for Experimental Medical Research, Istanbul University, Istanbul, Turkey

Received 27 February 2009 ,Accepted 25 September 2009.

References 

  1. Dallongeville J, Lussier-Cacan S, Davignon S. Modulation of plasma triglyceride levels by apoE phenotype: a meta-analysis. J Lipid Res. 1992;33:447–454
  2. Liu S, Ma J, Ridker PM, Breslow JL, Stampfer MJ. A prospective study of the APOE genotype and the risk of myocardial infarction among apparently healthy men. Atherosclerosis. 2004;166:323–329
  3. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA. 2007;298:1300–1311
  4. Mänttäri M, Manninen V, Palosuo T, Ehnholm C. Apolipoprotein E polymorphism and C-reactive protein in dyslipidemic middle-aged men (letter). Atherosclerosis. 2001;156:237–238
  5. Austin MA, Zhang C, Humphries SE, Chandler WL, Talmud PJ, Edwards KL, et al. Heritability of C-reactive protein and association with apolipoprotein E genotypes in Japanese Americans. Ann Hum Genet. 2004;68:179–188
  6. Judson R, Brain C, Dain B, Windemuth A, Ruano G, Reed C. New and confirmatory evidence of an association between APOE genotype and baseline C-reactive protein in dyslipidemic individuals. Atherosclerosis. 2004;177:345–351
  7. Eiriksdottir G, Aspelund T, Bjarnadottir K, Olafsdottir E, Gudnason V. Apolipoprotein E genotype and statins affect CRP levels through independent and different mechanisms: AGES Reykjavik Study (letter). Atherosclerosis. 2006;186:222–224
  8. Errera FIV, Silva MER, Yeh E, Maranduba CMC, Folco B, Takahashi W, et al. Effect of polymorphism of the MTHFR and APOE genes on susceptibility to diabetes and severity of diabetic retinopathy in Brazialian patients. Braz J Med Biol Res. 2006;39:883–888
  9. Onat A, Hergenç G, Can G. Serum C-reactive protein as an independent risk factor predicting cardiometabolic risk. Metabolism. 2008;57:207–214
  10. Onat A, Can G, Hergenç G. Yazıcı M, Karabulut A, Albayrak S. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension, diabetes, independent of markers of central obesity and inflammation. Int J Obes Relat Metab Disord. 2007;31:1119–1125
  11. Onat A, Hergenç G, Bulur S. Uğur M, Küçükdurmaz Z, Can G. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. Int J Cardiol. 2008;135:211–217
  12. Onat A, Can G, Ayhan E, Kaya Z, Hergenç G. Impaired protection against diabetes and coronary disease by high-density lipoproteins in Turks. Metabolism. 2009;58:1393–1399
  13. Onat A, Hergenç G, Can G, Küçükdurmaz Z. Serum adiponectin confers little protection against diabetes and hypertension in Turkish men. Obesity. 2008;17:564–570
  14. Schiele F, De Bacquer D, Vincent-Viry M, Beisiegel U, Ehnholm C, Evans A, et al. The ApoEurope group. Apolipoprotein E serum concentration and polymorphism in six European countries: the ApoEurope Project. Atherosclerosis. 2000;152:475–488
  15. Schiele F, Vincent-Viry M, Starck M, Beaud B, Hennache G, Siest G, et al. Apolipoprotein E in apolipoprotein B (apo B)- and non–apo B–containing lipoproteins in 3523 participants in the Stanislas Cohort: biological variation and genotype-specific reference limits. Clin Chem. 2002;48:291–300
  16. Boerwinkle E, Utermann G. Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. Am J Hum Genet. 1988;42:104–112
  17. Zerba KE, Ferrell RE, Sing CF. Complex adaptive systems and human health: the influence of common genotypes of the apolipoprotein E (apoE) gene polymorphism and age on the relational order within a field of lipid metabolism traits. Hum Genet. 2000;107:466–485
  18. Onat A, Ceyhan K, Başar Ö, Erer B, Toprak S, Sansoy V. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels—a prospective and cross-sectional evaluation. Atherosclerosis. 2002;165:285–292
  19. Onat A, Avcı GŞ, Şenocak M, Örnek E, Gözükara Y. Plasma lipids and their interrelation in Turkish adults. J Epidemiol Community Health. 1992;46:470–476
  20. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  21. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433–438
  22. Onat A, Uyarel H, Hergenç G, Karabulut A, Albayrak S, Can G. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis. 2007;191:182–190
  23. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al. Follow-up report on the diagnosis of diabetes mellitus. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2003;26:3160–3167
  24. Mahley RW, Palaoğlu E, Atak Z, Dawson-Pepin J, Langlois AM, Cheung V, et al. Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. J Lipid Res. 1995;36:839–859
  25. Ogasawara K, Mashiba S, Hashimoto H, Kojima S, Matsuno S, Takeya M, et al. Low-density lipoprotein (LDL), which includes apolipoprotein A-I (apoAI-LDL) as a novel marker of coronary artery disease. Clin Chim Acta. 2008;397:42–47
  26. Onat A, Hergenç G, Ayhan E, Kaya Z, Küçükdurmaz Z, Bulur S, et al. Serum apolipoprotein E concentrations among Turks: additive information to genotype relative to dyslipidemia and metabolic syndrome. Arch Turk Soc Cardiol. 2007;35:449–457
  27. Morcillo S, Cardona F, Rojo-Martinez G, Esteva I, Ruiz-de-Adana MS, Tinahones F, et al. Association between MspI polymorphism of the APO AI gene and type 2 diabetes mellitus. Diabet Med. 2005;22:782–788
  28. Dodin S, Cunnane SC, Masse B, Lemay A, Jacques H, Asselin G, et al. Flaxseed on cardiovascular disease markers in healthy menopausal women: a randomized, double-blind, placebo-controlled trial. Nutrition. 2008;24:23–30
  29. Greenow K, Pearce NJ, Ramji DP. The key role of apolipoprotein E in atherosclerosis. J Mol Med. 2005;83:329–342

 The Turkish Adult Risk Factor Surveys 2005–2008 were supported by the Turkish Society of Cardiology and the pharmaceutical and nutritional companies AstraZeneca, Novartis, Pfizer, SanofiAventis, and Danone, Istanbul, Turkey.

PII: S0899-9007(09)00417-1

doi: 10.1016/j.nut.2009.09.023

Nutrition
Volume 26, Issue 10 , Pages 975-980 , October 2010

Article Tools